No Data
Nanxin Pharmaceutical: Nanxin Pharmaceutical Report for the Third Quarter of 2024
Nanxin Pharmaceutical Report for the Third Quarter of 2024
Nucien Pharmaceutical's Q3 Profit Rises 2%
Nucien Pharmaceutical to Offload Loss-Making Subsidiary
hunan nucien pharmaceutical co., ltd. (688189.SH): pre-listing transfer of 100% equity of its wholly-owned subsidiary.
On October 23, GeLunHui reported that hunan nucien pharmaceutical co., ltd. (688189.SH) announced that, based on the company's overall operation plan and business structure, combined with industry development, in order to further optimize the company's management architecture, reduce management costs, and improve overall operational efficiency, the company plans to transfer 100% equity of its wholly-owned subsidiary Changde Zhencheng by way of public listing on the Hunan United Exchange. According to relevant regulations of state-owned asset supervision, after the pre-listing of this transaction, a formal listing and trading conditions will be subject to the formal listing. After this pre-listing, the company will proceed with the corresponding approval procedures based on the audit and evaluation results.
hunan nucien pharmaceutical co., ltd. (688189.SH): has cumulatively repurchased 0.4479% of the company's shares.
As of August 31, 2024, hunan nucien pharmaceutical co., ltd. (688189.SH) announced that the company has cumulatively repurchased 1,228,955 shares of the company's stock through the Shanghai Stock Exchange trading system by means of centralized bidding, accounting for 0.4479% of the total share capital of 274,400,000 shares. The highest price of the repurchase transaction was 9.24 yuan per share, and the lowest price was 5.45 yuan per share. The total amount of funds paid was RMB 7,997,384.37 (excluding stamp duty, transaction commissions, and other transaction fees).
No Data
No Data